CVS to Cover Lilly’s GLP-1 Medications, Expanding Access
CVS Health will broaden coverage for Lilly’s GLP-1 medications, including the new pill Foundayo and Zepbound injectio...
Learn which indices traders watch most closely and why. This quick primer covers the benchmarks that shape trading strategies and risk assessment.
26,463 articlesCVS Health will broaden coverage for Lilly’s GLP-1 medications, including the new pill Foundayo and Zepbound injectio...
ON Semiconductor is rising fast as 2025's downturn loosens its grip. This report explores the catalysts, risks, and t...
A Sunrun co-founder disclosed the sale of 50,000 shares, prompting questions about timing and implications. This arti...
Morgan Stanley filed amended SEC registrations for Ethereum and Solana ETFs, proposing a 14-basis-point sponsorship f...
A breakthrough budget EV pickup priced at $24,950 hits the market, backed by high-profile investors. Analysts questio...
As the U.S. nears its 250th birthday, Wendy Schmidt unveils a major science funding program aimed at accelerating bre...
A historic heat dome pushed the PJM grid toward an all-time peak. This investing backdrop highlights four power stock...
Insider moves can signal a lot about a company’s near-term plans and risk. This deep dive looks at Adaptive Biotechno...
Palantir faces a pivotal investor update that could move the stock. This guide breaks down the risks, catalysts, and ...
As quantum technology moves from labs to real-world use, a single stock could unlock big gains. This article explains...
Indiana approves a compromise housing reform package that narrows some local zoning controls while expanding by-right...
As Vivid Seats reports Q4 2025 results, investors face a pivotal moment. This article breaks down revenue drivers, ma...